ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 145 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $451,350 | -78.5% | 85,000 | -61.4% | 0.01% | -81.1% |
Q2 2023 | $2,096,600 | +172.3% | 220,000 | +214.3% | 0.04% | +146.7% |
Q1 2023 | $770,000 | -81.1% | 70,000 | -74.6% | 0.02% | -76.6% |
Q4 2022 | $4,084,800 | +228.9% | 276,000 | +324.6% | 0.06% | +276.5% |
Q3 2022 | $1,242,000 | +4.2% | 65,000 | +16.3% | 0.02% | 0.0% |
Q2 2022 | $1,192,000 | +210.4% | 55,910 | +202.2% | 0.02% | +325.0% |
Q4 2021 | $384,000 | – | 18,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,434,232 | $162,443,000 | 13.84% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76,641,000 | 7.44% |
Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,960,000 | 5.19% |
Logos Global Management LP | 1,500,000 | $28,890,000 | 3.75% |
Omega Fund Management, LLC | 623,836 | $12,015,000 | 2.46% |
Orbimed Advisors | 6,073,850 | $116,982,000 | 1.90% |
MPM BioImpact LLC | 258,500 | $4,979,000 | 1.34% |
1492 Capital Management LLC | 75,192 | $1,448,000 | 0.77% |
SECTORAL ASSET MANAGEMENT INC | 219,136 | $4,221,000 | 0.75% |
EcoR1 Capital, LLC | 895,503 | $17,247,000 | 0.54% |